NCT03538314View on ClinicalTrials.gov

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

October 1, 2022

Study Completion Date

June 15, 2024

Conditions
Malignant Melanoma
Interventions
DRUG

UV1

UV1 (300 microgram)

DRUG

GM-CSF

GM-CSF (37,5 or 75 microgram)

Trial Locations (4)

18045

St. Luke's University Health Network, Easton

52242

University of Iowa Carver College of Medicine, Iowa City

84112

University of Utah Huntsman Cancer Institute, Salt Lake City

90404

John Wayne Cancer Center, Santa Monica

All Listed Sponsors
lead

Ultimovacs ASA

INDUSTRY

NCT03538314 - UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma | Biotech Hunter | Biotech Hunter